Hansa Biopharma AB Stock Mexican S.E.

Equities

HNSA N

SE0002148817

Biotechnology & Medical Research

End-of-day quote Mexican S.E. 07:00:00 2023-03-15 pm EDT 5-day change 1st Jan Change
160.8 MXN -.--% Intraday chart for Hansa Biopharma AB -.--% -.--%

Financials

Sales 2024 * 252M 23.95M 423M Sales 2025 * 345M 32.77M 578M Capitalization 3.36B 319M 5.63B
Net income 2024 * -679M -64.51M -1.14B Net income 2025 * -693M -65.84M -1.16B EV / Sales 2024 * 14.9 x
Net Debt 2024 * 404M 38.38M 677M Net Debt 2025 * 815M 77.46M 1.37B EV / Sales 2025 * 12.1 x
P/E ratio 2024 *
-4.56 x
P/E ratio 2025 *
-5.56 x
Employees 166
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.64%
More Fundamentals * Assessed data
Dynamic Chart
3 years
160.75
Extreme 160.75
160.75
5 years
160.75
Extreme 160.75
160.75
10 years
160.75
Extreme 160.75
160.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 18-03-19
Chief Tech/Sci/R&D Officer 53 Nov. 30
Chief Tech/Sci/R&D Officer 66 20-05-28
Members of the board TitleAgeSince
Director/Board Member 73 18-05-28
Chairman 61 22-06-29
Director/Board Member 59 19-05-21
More insiders
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
49.52 SEK
Average target price
105 SEK
Spread / Average Target
+112.04%
Consensus